American College of Cardiology Meeting In Brief: Merck's Prinivil
Merck's Prinivil: Retrospective, subgroup analysis of diabetic patients from the GISSI-3 trial shows that treatment with Prinivil (lisinopril) within 24 hours of a suspected myocardial infarction results in a significant decrease in mortality at six weeks for both non-insulin dependent and insulin dependent diabetics, Giulio Zuanetti, Istituto Mario Negri, Milan, reported March 25 at ACC. NIDD patients (n=1,130) receiving lisinopril show a 22% reduction in mortality at six weeks compared to 1,164 NIDD patients receiving placebo, and IDD patients receiving lisinopril (n=254) show a 44.4% reduction in mortality at six weeks compared to 242 IDD patients receiving placebo. Survival rates for both NIDD and IDD patients receiving lisinopril at six weeks was 91% compared to 80% for NIDD and IDD patients on placebo (p=.0005)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth